Unmet treatment needs in schizophrenia patients: Is asenapine a potential therapeutic option?

Expert Review of Neurotherapeutics

Volumn 11, Issue 7, 2011, Pages 989-1006

  Pompili, Maurizio ^a,b   Serafini, Gianluca ^a   Innamorati, Marco ^a   Ambrosi, Elisa ^a   Telesforo, Ludovica ^a   Venturini, Paola ^a   Giordano, Gloria ^a   Battuello, Michele ^a   Lester, David ^c   Girardi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MCLEAN HOSPITAL   (United States)

^c RICHARD STOCKTON COLLEGE OF NEW JERSEY   (United States)

Author keywords

adherence; antipsychotics; asenapine; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; GLUCOSE; HALOPERIDOL; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; BINDING AFFINITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COGNITION; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYNDROME; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIVER FUNCTION TEST; METABOLIC DISORDER; MOTOR DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORTHOSTATIC HYPERTENSION; PATIENT COMPLIANCE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDE; SYNCOPE; TARDIVE DYSKINESIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MEDICATION ADHERENCE; SCHIZOPHRENIA;

EID: 79959948500     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.82     Document Type: Review

References (174)

1. Pompili M, Lester D, Innamorati M, Tatarelli R, Girardi P. Assessment and treatment of suicide risk in schizophrenia. Expert Rev. Neurother. 8(1), 51-74 (2008).
2. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. American Psychiatric Association, DC, USA (2004).
3. Green MF. Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu. Rev. Clin. Psychol. 3, 159-180 (2007). (Pubitemid 46651125)
4. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153(3), 321-330 (1996). (Pubitemid 26074706)
5. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12(3), 426-445 (1998). (Pubitemid 28323862)
6. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158(2), 176-184 (2001). (Pubitemid 32116511)
7. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25(2), 201-222 (1999). (Pubitemid 29272501)
8. Keefe RS, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry 161(6), 985-995 (2004). (Pubitemid 38735984)
9. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25(2), 233-255 (1999). (Pubitemid 29272503)
10. Green MF, Marder SR, Glynn SM et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry 51(12), 972-978 (2002). (Pubitemid 34607714)
11. Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64(6), 633-647 (2007 (Pubitemid 46878665)
12. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J. Clin. Psychopharmacol. 24(5 Suppl. 1), S7-S14 (2004). (Pubitemid 39265949)
13. Nagamoto HT. Antipsychotic medications. In:Psychiatric Secrets. Jacobson JL, Jacobson AM (Eds). Hanley and Belfus Inc., PA, USA, 253-259 (2001).
14. Kane JM. Schizophrenia. N. Engl .J. Med. 334(1), 34-41 (1996). (Pubitemid 126528534)
15. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res. 66(1), 51-57 (2004). (Pubitemid 38030344)
16. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int. Clin. Psychopharmacol. 16(3), 153-162 (2001). (Pubitemid 32402360)
17. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321(7273), 1371-1376 (2000).
18. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry 160(7), 1209-1222 (2003). (Pubitemid 41070936)
19. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161(3), 414-425 (2004). (Pubitemid 38326094)
20. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28(Suppl. 1), 9-26 (2003). (Pubitemid 36015659)
21. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60(6), 553-564 (2003). (Pubitemid 36682312)
22. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry 177, 212-217 (2000).
23. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2), 596-601 (2004).
24. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 17(6), 423-430 (2003). (Pubitemid 36560704)
25. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry 61(10), 742-749 (2000).
26. Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry 157(6), 975-981 (2000). (Pubitemid 30412350)
27. Casey DE, Haupt DW, Newcomer JW et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J. Clin. Psychiatry 65(Suppl. 7), 4-18; quiz 19-20 (2004).
28. Fontaine KR, Heo M, Harrigan EP et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 101(3), 277-288 (2001). (Pubitemid 32324233)
29. Newcomer JW, Haupt DW, Fucetola R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 59(4), 337-345 (2002). (Pubitemid 34275252)
30. Tandon R, Belmaker RH, Gattaz WF et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 100(1-3), 20-38 (2008).
31. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657), 31-41 (2009).
32. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14(4), 429-447 (2009).
33. Boter H, Peuskens J, Libiger J et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr. Res. 115(2-3), 97-103 (2009).
34. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005). (Pubitemid 41345943)
35. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 63(12), 1121-1128 (2002). (Pubitemid 36084056)
36. Tacchi MJ, Scott J. Improving Adherence in Schizophrenia and Bipolar Disorders. Wiley, Chichester, UK (2005).
37. Tatarelli R. Drugs and human interactions. Ann. Ist Super Sanita 28(2), 197-202 (1992).
38. Noble LM. Doctor-patient communication and adherence to treatment. In:Adherence to Treatment in Medical Conditions. Myer LB, Midence K (Eds). Wiley, London, UK, 51-82 (1998).
39. Valenstein M, Blow FC, Copeland LA et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr. Bull. 30(2), 255-264 (2004). (Pubitemid 38828533)
40. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv. 49(2), 196-201 (1998). (Pubitemid 28071427)
41. Davis JM, Kane JM, Marder SR et al. Dose response of prophylactic antipsychotics. J. Clin. Psychiatry 54(Suppl.), 24-30 (1993). (Pubitemid 23121853)
42. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull. 23(4), 637-651 (1997). (Pubitemid 27485972)
43. Robinson D, Woerner MG, Alvir JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 56(3), 241-247 (1999). (Pubitemid 29125132)
44. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr. Serv. 54(5), 719-723 (2003). (Pubitemid 36752965)
45. Gilmer TP, Dolder CR, Lacro JP et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 161(4), 692-699 (2004). (Pubitemid 38445514)
46. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry 68(Suppl. 4), 8-13 (2007). (Pubitemid 46762118)
47. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J. Clin. Psychiatry 68(Suppl. 4), 4-7 (2007).
48. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry 64(10), 1123-1131 (2007). (Pubitemid 47529346)
49. Gough SC, ODonovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J. Psychopharmacol. 19(6 Suppl.), 47-55 (2005 (Pubitemid 44567858)
50. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 24(5), 481-485 (2007). (Pubitemid 46669314)
51. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl. 1), 1-93 (2005). (Pubitemid 40677047)
52. Sengupta S, Parrilla-Escobar MA, Klink R et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls? Schizophr. Res. 102(1-3), 329-336 (2008).
53. Newcomer JW. Metabolic risk during antipsychotic treatment. Clin. Ther. 26(12), 1936-1946 (2004). (Pubitemid 40353605)
54. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can. J. Psychiatry 51(8), 492-501 (2006). (Pubitemid 44166337)
55. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8(1), 15-22 (2009).
56. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 45(1-2), 21-28 (2000).
57. Johnsen E. Review: metabolic side effects of second-generation antipsychotics. Evid. Based Ment. Health 14(2), 47 (2011).
58. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur. Psychiatry 26(3), 144-158 (2011).
59. DeBattista C, DeBattista K. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. Curr. Drug Saf. 5(3), 263-266 (2010).
60. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv. Rev. Psychiatry 14(3), 152-164 (2006). (Pubitemid 43995124)
61. Rummel-Kluge C, Komossa K, Schwarz S et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 123(2-3), 225-233 (2010).
62. Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim. Care Diabetes 3(1), 5-15 (2009).
63. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 70(1), 1-17 (2004). (Pubitemid 38916622)
64. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr. Scand. 119(3), 171-179 (2009).
65. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr. Opin. Endocrinol. Diabetes Obes. 17(5), 460-466 (2010).
66. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31(10), 2091-2120 (2006). (Pubitemid 44413188)
67. Rondanelli M, Sarra S, Antoniello N et al. No effect of atypical antipsychotic drugs on weight gain and risk of developing Type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimers disease. Minerva Med. 97(2), 147-151 (2006). (Pubitemid 43966273)
68. Kinon BJ, Volavka J, Stauffer V et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J. Clin. Psychopharmacol. 28(4), 392-400 (2008).
69. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
70. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21), 2709-2716 (2002). (Pubitemid 35403784)
71. Haupt DW, Newcomer JW. Abnormalities in glucose regulation associated with mental illness and treatment. J. Psychosom. Res. 53(4), 925-933 (2002). (Pubitemid 35282624)
72. McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80(1), 19-32 (2005). (Pubitemid 41587460)
73. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand. 119(1), 4-14 (2009).
74. De Hert M, Schreurs V, Sweers K et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res. 101(1-3), 295-303 (2008).
75. Baldessarini RJ. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 360(20), 2136-2137; author reply 2137-2138 (2009).
76. Correll CU, Harris JL, Pantaleon Moya RA, Frederickson AM, Kane JM, Manu P. Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities. Schizophr. Res. 92(1-3), 103-107 (2007). (Pubitemid 46561219)
77. Barnett AH, Millar HL, Loze JY, LItalien GJ, van Baardewijk M, Knapp M. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). Eur. Arch. Psychiatry Clin. Neurosci. 259(4), 239-247 (2009).
78. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 360(3), 225-235 (2009).
79. Correll CU, Frederickson AM, Figen V et al. The QTc interval and its dispersion in patients receiving two atypical antipsychotics. Eur. Arch. Psychiatry Clin. Neurosci. 259(1), 23-27 (2009).
80. Harrigan EP, Miceli JJ, Anziano R et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. 24(1), 62-69 (2004). (Pubitemid 38134167)
81. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry 158(11), 1774-1782 (2001). (Pubitemid 33054769)
82. Fenton M, Rathbone J, Reilly J, Sultana A. Thioridazine for schizophrenia. Cochrane Database Syst. Rev. (3), CD001944 (2007).
83. Elbe D, Carandang CG. Focus on ziprasidone: a review of its use in child and adolescent psychiatry. J. Can. Acad. Child Adolesc. Psychiatry 17(4), 220-229 (2008
84. Jolly K, Gammage MD, Cheng KK, Bradburn P, Banting MV, Langman MJ. Sudden death in patients receiving drugs tending to prolong the QT interval. Br. J. Clin. Pharmacol. 68(5), 743-751 (2009).
85. Mackin P. Cardiac side effects of psychiatric drugs. Hum. Psychopharmacol. 23(Suppl. 1), 3-14 (2008).
86. Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann. Pharmacother. 31(7-8), 867-870 (1997). (Pubitemid 27332477)
87. Cysneiros RM, Terra VC, Machado HR et al. May the best friend be an enemy if not recognized early: possible role of omega-3 against cardiovascular abnormalities due to antipsychotics in the treatment of autism. Arq. Neuropsiquiatr. 67(3B), 922-926 (2009).
88. Tiihonen J, Lonnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690), 620-627 (2009).
89. Taylor D. Typical and atypical antipsychotics increase risk of sudden cardiac death. Evid. Based Ment. Health 12(3), 92 (2009).
90. Herrmann N, Lanctot KL. Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned? Drug Saf. 29(10), 833-843 (2006). (Pubitemid 44511585)
91. Jerrell JM, McIntyre RS. Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Hum. Psychopharmacol. 22(6), 361-364 (2007). (Pubitemid 47316119)
92. Roh S, Ahn DH, Nam JH, Yang BH, Lee BH, Kim YS. Cardiomyopathy associated with clozapine. Exp. Clin. Psychopharmacol. 14(1), 94-98 (2006).
93. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21(11), 911-936 (2007). (Pubitemid 47557106)
94. Dodd ML, Dolenc TJ, Karpyak VM, Rasmussen KG. QTc dispersion in patients referred for electroconvulsive therapy. J. Ect. 24(2), 131-133 (2008).
95. Schneider RA, Lizer MH. Apparent seizure and atrial fibrillation associated with paliperidone. Am. J. Health Syst. Pharm. 65(22), 2122-2125 (2008).
96. Wang JF, Min JY, Hampton TG et al. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur. J. Pharmacol. 592(1-3), 123-127 (2008).
97. Ariyarajah V, Shaikh N, Garber PJ, Kirkpatrick I, McGregor R, Jassal DS. Cardiovascular magnetic resonance in mild to moderate clozapine-induced myocarditis: is there a role in the absence of electrocardiographic and echocardiographic abnormalities? J. Magn. Reson. Imaging 31(6), 1473-1476 (2010).
98. Nahshoni E, Strasberg B, Imbar S et al. Late potentials in the signal-averaged electrocardiogram in schizophrenia patients maintained on antipsychotic agents: a preliminary naturalistic study. Eur. Neuropsychopharmacol. 20(3), 146-152 (2010).
99. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 13(2), 137-177 (2007). (Pubitemid 47052346)
100. Nakagawa S, Pedersen L, Olsen ML, Mortensen PB, Sorensen HT, Johnsen SP. Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. J. Intern. Med. 260(5), 451-458 (2006). (Pubitemid 44571133)
101. Riedel M, Eich FX, Moller HJ. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. Eur. Psychiatry 24(3), 149-153 (2009).
102. Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry Clin. Neurosci. 64(1), 104-106 (2010).
103. Razminia M, Salem Y, Devaki S, Shah N, Khosla S. Clozapine induced myopericarditis: early recognition improves clinical outcome. Am. J. Ther. 13(3), 274-276 (2006). (Pubitemid 44026195)
104. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr. Serv. 54(4), 508-516 (2003). (Pubitemid 36752981)
105. Rittmannsberger H, Pachinger T, Keppelmuller P, Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr. Serv. 55(2), 174-179 (2004). (Pubitemid 38174608)
106. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 168, 603-609 (2011).
107. Palmer CS, Brunner E, Ruiz-Flores LG, Paez-Agraz F, Revicki DA. A cost-effectiveness clinical decision analysis model for treatment of schizophrenia. Arch. Med. Res. 33(6), 572-580 (2002). (Pubitemid 36026616)
108. Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18(1), 41-49 (1998). (Pubitemid 28116372)
109. Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: II. Cost-effectiveness. Clin. Ther. 20(1), 196-213 (1998). (Pubitemid 28126292)
110. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am. J. Manag. Care 4(3), 345-355 (1998). (Pubitemid 28350792)
111. Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost- effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. J. Eval. Clin. Pract. 13(3), 453-460 (2007). (Pubitemid 46789653)
112. Rosenheck RA, Leslie DL, Sindelar J et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry 163(12), 2080-2089 (2006). (Pubitemid 46114227)
113. Polsky D, Doshi JA, Bauer MS, Glick HA. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am. J. Psychiatry 163(12), 2047-2056 (2006). (Pubitemid 46114222)
114. Rosenheck RA, Perlick D, Bingham S et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290(20), 2693-2702 (2003). (Pubitemid 37475597)
115. Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health 7(1), 22-35 (2004). (Pubitemid 38186282)
116. Hargreaves WA, Gibson PJ. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs 19(5), 393-410 (2005). (Pubitemid 41124014)
117. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 9(2), 77-89 (2006). (Pubitemid 44044740)
118. Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 7(5), 569-584 (2004 (Pubitemid 39390837)
119. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, just the facts 4. Clinical features and conceptualization. Schizophr. Res. 110(1-3), 1-23 (2009).
120. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, just the facts 5. Treatment and prevention. Past, present, and future. Schizophr. Res. 122(1-3), 1-23 (2010).
121. Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin. Neurosci. 12(3), 345-357 (2010).
122. Patterson TL, Leeuwenkamp OR. Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr. Res. 100(1-3), 108-119 (2008).
123. Costall B, Domeney AM, Kelly ME, Naylor RJ, Tomkins DM. Actions of ORG 5222 as a novel psychotropic agent. Pharmacol. Biochem. Behav. 35(3), 607-615 (1990). (Pubitemid 20115748)
124. Shahid M, Wong E, Walker GB, Baker RA, Jina AS, Zorn S. Asenapine: a novel psychotherapeutic agent with a unique human receptor binding signature. Presented at: ACNP 2005 Annual Meeting. Waikoloa, HI, USA, 11-15 December (2005).
125. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol 23(1), 65-73 (2009).
126. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68(1), 29-39 (2000).
127. Potkin SG, Cohen M, Baker RA et al. Asenapine, a novel psychopharmacologic agent with efficacy in positive and negative symptoms during acute episodes of schizophrenia: a randomized, placebo and risperidone- controlled trial. Presented at: ACNP 2005 Annual Meeting. HI, USA, 11-15 December (2005).
128. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J. Clin. Psychopharmacol. 30(2), 106-115 (2010).
129. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int. J. Clin. Pract. 63(12), 1762-1784 (2009).
130. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 43(4), 138-146 (2010).
131. Chapel S, Hutmacher MM, Haig G et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J. Clin. Pharmacol. 49(11), 1297-1308 (2009).
132. Preskorn S, Chapel. S, Panagides J. Effect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophrenia. Eur. Neuropsychopharmacol. 17(Suppl. 4), S453 (2007).
133. Fleming K, Potkin SG, Binneman B, Keller DS, Alphs L, Panagides J. Asenapine improves cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Presented at: American Psychiatric Association 160th Annual Meeting. CA, USA, 19-24 May (2007).
134. Fleming K, Potkin SG, Binneman B, Keller D, Alph sL, Panagides J. Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Eur. Neuropsychopharmacol. 17(Suppl. 4), S466 (2007).
135. Potkin SG, Fleming K, Binneman B, Keller DS, Alphs L, Panagides J. Asenapine cognitive function effects in acute schizophrenia: a placebo- and risperidone-controlled trial. Presented at: American Psychiatric Association 160th Annual Meeting. San Diego, CA, USA, 19-24 May (2007).
136. Alphs L, Panagides J, Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale. Psychopharmacol. Bull. 40(2), 41-53 (2007).
137. Tarazi FI, Moran-Gates T, Massari C, Wong EHF, Henry B, Shahid M. Asenapine displays unique long-term molecular effects on dopamine receptor subtypes. Presented at: ACNP 2005 Annual Meeting. Waikoloa, HI, USA, 11-15 December (2005).
138. Minassian A, Young JW. Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin. Pharmacother. 11(12), 2107-2115 (2010).
139. US FDA. Saphris (Asenapine) sublingual tablets. Briefing book. US FDA, MD, USA (2009).
140. McIntyre RS. Asenapine: a review of acute and extension phase data in bipolar disorder. CNS Neurosci. Ther. DOI: 10.1111/j.1755-5949.2010.00200.x (2010) (Epub ahead of print).
141. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am. J. Psychiatry 159(1), 103-108 (2002). (Pubitemid 41070734)
142. Garcia Cabeza I, Sanchez Diaz EI, Sanz Amador M, Gutierrez Rodriguez M, Gonzalez de Chavez M. [Factors related to treatment adherence in schizophrenic patients]. Actas Esp. Psiquiatr. 27(4), 211-216 (1999).
143. McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR. Use patterns for antipsychotic medications in medicaid patients with schizophrenia. J. Clin. Psychiatry 60(Suppl. 19), 5-11; discussion 12-13 (1999). (Pubitemid 29446944)
144. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr. Serv. 54(5), 665-667 (2003). (Pubitemid 36752956)
145. Thomas P. The stable patient with schizophrenia - from antipsychotic effectiveness to adherence. Eur. Neuropsychopharmacol. 17(Suppl. 2), S115-S122 (2007).
146. Perkins DO. Clinical trials in schizophrenia with results for the real world. CNS Spectr. 11(7 Suppl. 7), 9-13 (2006). (Pubitemid 44141224)
147. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J. Neural Transm. 109(3), 411-420 (2002). (Pubitemid 34251643)
148. Hudson TJ, Owen RR, Thrush CR et al. A pilot study of barriers to medication adherence in schizophrenia. J. Clin. Psychiatry 65(2), 211-216 (2004).
149. Mojtabai R, Lavelle J, Gibson PJ et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr. Serv. 53(3), 337-339 (2002). (Pubitemid 34184688)
150. Vanelli M, Burstein P, Cramer J. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr. Serv. 52(9), 1248-1250 (2001). (Pubitemid 32823200)
151. Grunebaum MF, Weiden PJ, Olfson M. Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J. Clin. Psychiatry 62(5), 394-399; quiz 400-391 (2001). (Pubitemid 32545566)
152. Cabeza IG, Amador MS, Lopez CA, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr. Res. 41(2), 349-355 (2000 (Pubitemid 30077477)
153. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch. Gen. Psychiatry 63(6), 679-685 (2006). (Pubitemid 43848299)
154. Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J. Clin. Psychiatry 59(Suppl. 3), 31-37 (1998).
155. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18(13), 877-893 (2004). (Pubitemid 39612017)
156. Voruganti LN, Cortese L, Owyeumi L et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr. Res. 57(2-3), 201-208 (2002).
157. Voruganti LN, Heslegrave RJ, Awad AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J. Psychiatry Neurosci. 22(4), 267-274 (1997). (Pubitemid 127488589)
158. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int. Clin. Psychopharmacol. 10(Suppl. 3), 123-132 (1995). (Pubitemid 26054886)
159. Day JC, Bentall RP, Roberts C et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch. Gen. Psychiatry 62(7), 717-724 (2005). (Pubitemid 41002752)
160. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J. Clin. Psychiatry 68(Suppl. 4), 14-18 (2007). (Pubitemid 46762119)
161. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J. Clin. Psychiatry 68(Suppl. 4), 34-39 (2007). (Pubitemid 46762121)
162. Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. J. Clin. Psychiatry 68(Suppl. 4), 19-25 (2007). (Pubitemid 46766508)
163. Vreeland B. Bridging the gap between mental and physical health: a multidisciplinary approach. J. Clin. Psychiatry 68(Suppl. 4), 26-33 (2007). (Pubitemid 46762120)
164. Goff DC. Integrating general health care in private community psychiatry practice. J. Clin. Psychiatry 68(Suppl. 4), 49-54 (2007). (Pubitemid 46762124)
165. Parks JJ. Implementing practice guidelines: lessons from public mental health settings. J. Clin. Psychiatry 68(Suppl. 4), 45-48 (2007). (Pubitemid 46762123)
166. Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J. Clin. Psychiatry 68(Suppl. 4), 40-44 (2007). (Pubitemid 46762122)
167. Pompili M, Girardi P, Ruberto A, Tatarelli R. Toward a new prevention of suicide in schizophrenia. World J. Biol. Psychiatry 5(4), 201-210 (2004). (Pubitemid 44121699)
168. Komossa K, Rummel-Kluge C, Hunger H et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (3), CD006654 (2010).
169. Komossa K, Rummel-Kluge C, Schmid F et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (1), CD006625 (2010).
170. Komossa K, Rummel-Kluge C, Hunger H et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (1), CD006624 (2010).
171. Komossa K, Rummel-Kluge C, Hunger H et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (4), CD006627 (2009).
172. Komossa K, Rummel-Kluge C, Schmid F et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (4), CD006569 (2009).
173. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. (3), CD002306 (2000).
174. McEvoy JP, Lieberman JA, Perkins DO et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 164(7), 1050-1060 (2007). (Pubitemid 47121394)